IN THE CLAIMS

1. (Cancelled)

2. (Currently amended) The method according to claim ~~1~~ 7 wherein the inhibitor is sildenafil.

3. (Currently amended) The method according to either claim 12 ~~1~~ wherein the PDE5 inhibitor has an IC50 against the PDE5 enzyme of less than 100 nanomolar.

4. (Original) The method according to claim 3 wherein the PDE5 inhibitor has a selectivity over PDE3 of greater than 100 fold.

5. (Original) The method according to claim 4 wherein the PDE5 inhibitor has a selectivity over both PDE3 and PDE4 of greater than 100 fold.

6. (Original) The method according to claim 5 wherein the PDE5 inhibitor has an IC50 against PDE5 of less than 100 nM and a selectivity over PDE3 of greater than 100 fold.

7. (Currently amended) The method according to claim 12 wherein the PDE5 inhibitor is selected from the group:

5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil);

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351);

2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil);

5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and

5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one and pharmaceutically acceptable salts thereof.

8. Cancelled.

9. (Currently amended) The method according to claim 7 ~~8~~ wherein the daily dosage is 5 to 500 mg.

10. (Original) The method according to claim 9 wherein the daily dosage is 10 to 100 mg.

11. Cancelled.

12. (New) A method for treating premature ejaculation in patients with normal erectile function comprising administering an effective amount of a PDE5 inhibitor in combination with one or more α-adrenergic receptor antagonists, NPY inhibitors, melanocortin enhancers, 5-HT_3 or 5-HT_4 antagonists, modulator of transporters for noradrenaline, dopamine and/or serotonin or anti-depressants.

13. (New) The method according to Claim 13 wherein the anti-depressant is a selective serotonin re-uptake inhibitor.